Professor Andrew Wei (MB,BS, PhD) is a clinical haematologist [MBBS 1993, FRACP 2002 (Haematology)], haematopathologist [FRCPA 2002], current National Health and Medical Research Council (NHMRC) clinical fellow, fellow of the Australian Academy of Health and Medical Sciences and specialist in acute myeloid leukaemia and myelodysplastic syndromes at the Peter MacCallum Centre and the Royal Melbourne Hospital in Melbourne, Australia. Dr Wei holds a joint appointment as the Metcalf Family Fellow and laboratory head in the division of Blood Cells and Blood Cancer, Walter and Eliza Hall Institute of Medical Research, where his laboratory has studied novel venetoclax combinations and mechanisms of resistance to BH3-mimetic drugs in acute myeloid leukaemia. He received his MB,BS degrees from the University of Melbourne and completed PhD studies at the Walter and Eliza Hall Institute for Medical Research investigating apoptosis in blood cancers. Professor Wei has served as chair of the acute leukaemia and myelodysplastic syndrome working party for the Australasian Leukaemia & Lymphoma Group since 2009. His current interest is focussed on developing novel clinical trials, particularly for patients with TP53 mutation and to target measurable residual disease (MRD) to prevent relapsing disease. Dr Wei has continuously mentored clinical fellows to develop AML trials for over a decade and has served on the European LeukemiaNet AML committee and editorial boards of Blood and the Journal of Clinical Oncology.

Dr. Wei's research focuses on the mechanisms by which cancer cells co-opt and coerce intracellular signalling pathways to promote deregulated cell survival, proliferation and growth. Through the molecular analysis of intracellular signalling pathways, Dr. Wei's laboratory seeks to identify new therapeutic targets in leukaemia.

Projects:

1. Developing models of TP53 mutated AML
2. Understanding the molecular mechanisms of evolution to TP53 mutated AML
3. Developing novel therapies to target TP53 mutant leukemias

2022 - Present : Professor of Hematology- University of Melbourne

Investigator initiated AML trial funding:

• Phase 1 study of RAD001 and low dose ara-C for elderly AML
• Phase 1 study of azacitidine and lenalidomide as maintenance therapy in AML
• Phase 1 study of azacitidine and everolimus in relapsed AML
• Phase 1 multicentre ALLG study of lenalidomide maintenance therapy in AML
• Phase 2 randomised controlled multicentre ALLG study of Sorafenib in FLT3-ITD AML 
• Phase 2 randomised multicentre ALLG study of high-dose lenalidomide and azacitidine and depsipeptide in relapsed AML

Cooperative Group Studies Local Site PI:

• Phase 3 study: ALLG AML M12 study
• Phase 2 study: ALLG APML M4 study
• Phase 2/3: UK MRC16 AML study

Company sponsored studies as local site PI:

• Phase 2 study: CEP-701 in relapsed AML
• Phase 2 study: AS1411 in relapsed AML
• Phase 2 study: Midostaurin in systemic mastocytosis
• Phase 2/3 study: AZD1152 in older AML
• Phase 3 study: PKC412 in AML
• Phase 3 study: Amonafide in secondary AML
• Phase 3 study: Elacytarabine in relapsed AML
• Phase 3: Voreloxin in relapsed AML
• Phase 1: KB004 in advanced haematological malignancies
• Phase 1: Meisoindigo in AML unfit for chemotherapy